Literature DB >> 409950

Prostaglandin-producing suppressor cells in Hodgkin's disease.

J S Goodwin, R P Messner, A D Bankhurst, G T Peake, J H Saiki, R C Williams.   

Abstract

We examined the role of a prostaglandin-producing suppressor cell in the hyporesponsiveness to phytohemagglutinin seen in Hodgkin's disease. Addition of indomethacin to phytohemagglutinin cultures of lymphocytes from six patients with Hodgkin's disease resulted in an increase of 182 +/- 60 per cent in 3H-thymidine incorporation versus a 44 +/- 18% increase in 29 controls (mean +/- S.D., P less than 0.001). Without indomethacin the mean response of the lymphocytes in Hodgkin's disease was 48% of that of control. With indomethacin it was 94% of the control value. Phytohemagglutinin cultures of Hodgkin-disease lymphocytes produced approximately fourfold more prostaglandin E2 after 48 hours than did normal lymphocytes (P less than 0.02). Removal of glass-adherent cells markedly decreased the enhancement seen with indomethacin; it reduced prostaglandin E2 production by more than 80% and eliminated the differences in response to phytohemagglutinin between Hodgkin-disease and normal lymphocytes. Thus, a glass-adherent, prostaglandin-producing suppressor cell is responsible for the hyporesponsiveness to phytohemagglutinin seen with Hodgkin-disease lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 409950     DOI: 10.1056/NEJM197711032971802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  119 in total

Review 1.  [Hodgkin's disease. Results in diagnosis and treatment (author's transl)].

Authors:  D Huhn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-04-17

2.  Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease.

Authors:  F Griesinger; L Bergmann; R Barot-Ciorbaru; P S Mitrou
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Immunosuppressive actions of prostaglandins and the possible increase in chronic inflammation after cyclo-oxygenase inhibitors.

Authors:  G P Lewis; M L Barrett
Journal:  Agents Actions       Date:  1986-10

4.  Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen.

Authors:  A B Gottlieb; R G Lahita; N Chiorazzi; H G Kunkel
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

5.  Modulation by thymus-derived (T) cells of thyroid cell-stimulated prostaglandin E release by human peripheral blood mononuclear cells.

Authors:  M Yamamoto; N A Takai; B Rapoport; W E Hinds
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

6.  The effect of human monocytes and macrophages on lymphocyte proliferation.

Authors:  J H Passwell; M Levanon; J Davidsohn; F Kohen; B Ramot
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

7.  Influence of zymosan (a non-specific macrophage stimulator) and of indomethacin on liver tumours--an experimental study in rats.

Authors:  S B Holmberg; P L Naredi; G O Lindnér; I H Karlberg; P L Daneryd; L M Karlsson; A Pettersson; U Stenram; L R Hafström
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Influence of malaria infection on the elaboration of soluble mediators by adherent mononuclear cells.

Authors:  D J Wyler; J J Oppenheim; L C Koontz
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

9.  Effects of endogenous and exogenous inhibitors on the incorporation of labeled precursors into DNA by human mononuclear cells.

Authors:  T J Sims; R C Page
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

10.  Increased suppressor cell activity in inflammatory bowel disease.

Authors:  G Holdstock; B F Chastenay; E L Krawitt
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.